| Project/Area Number |
18K10065
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 58030:Hygiene and public health-related: excluding laboratory approach
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
的野 智光 鳥取大学, 医学部附属病院, その他 (60571841)
永原 天知 鳥取大学, 医学部附属病院, 助教 (00548860)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2021: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 肝細胞癌 / サーベイランス / 糖尿病 / FIB-4 index / Fib-4 index / 非B非C型 / ウイルス性肝細胞癌 / 非B非C型肝細胞癌 |
|---|
| Outline of Final Research Achievements |
For 414 cases diagnosed as primary hepatocellular carcinoma (HCC) at nine facilities in Tottori Prefecture from 2017 to 2019, surveillance for patients in the HCC high-risk group and risk factors for non-B non-C (NBNC) HCC were examined. The surveillance rate was 53.2% for hepatitis B virus (HBV), 32.8% for untreated hepatitis C virus (HCV), 95.5% for HCV (DAA-SVR), 68.8% for HCV (IFN-SVR), 14.0% for NBNC (non-ALD) (non-ALD; nonalcoholic), and 13.7% for NBNC (ALD). Patients who were HBV/HCV positive but were accidentally diagnosed with HCC didn't have a regular medical examination and had no history of HBV/HCV testing. The incidence of diabetes mellitus (DM) in 129 patients with NBNC (non-ALD) HCC was as high as 48.8%, and FIB-4 index 2.67 or higher was 35.7%. These results indicate that introduction of HCC surveillance for patients with DM and FIB-4 index 2.67 or higher may be able to diagnose about 30% of NBNC (non-ALD) HCC at early stages.
|
| Academic Significance and Societal Importance of the Research Achievements |
現在、非B非C型（NBNC）肝細胞癌（HCC）は偶発的に進行した状態で診断されることが多いが、FIB-4 index 2.67以上の糖尿病患者をその高危険群に設定してサーベイランスを行うことにより、NBNC HCC患者の予後改善が期待され、学術的・社会的意義は極めて大きいと考える。糖尿病かつFIB-4 index 2.67以上の条件を満たさないNBNC HCCやアルコール性HCCの早期診断対策は未解決の課題であり、今後の研究の進展が待たれる。
|
